Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 3 de 3
Filter
Add more filters










Database
Language
Publication year range
1.
Cytoskeleton (Hoboken) ; 69(8): 566-76, 2012 Aug.
Article in English | MEDLINE | ID: mdl-22903939

ABSTRACT

There are seven distinct ß-tubulin isotypes and eight α-tubulin isotypes in mammals that are hypothesized to have tissue- and cell-specific functions. There is an interest in the use of tubulin isotypes as prognostic markers of malignancy. ßV-tubulin, like ßIII-tubulin, has been implicated in malignant transformation and drug resistance, however little is known about its localization and function. Thus, we generated for the first time, a rabbit polyclonal antibody specific for human ßV-tubulin. The antibody did not cross-react with mouse ßV-tubulin or other human ß-tubulin isotypes and specifically labeled ßV-tubulin by immunoblotting, immunofluorescence and immunohistochemistry. Immunohistochemistry of various human normal tissues revealed that ßV-tubulin was expressed in endothelial cells, myocytes and cells with muscle differentiation, structures with transport and/or secretory function such as renal tubules, pancreatic ducts and bile ducts, and epithelium with secretory function such as prostate. ßV-tubulin was also specifically expressed in pancreatic islets and intratubular germ cell neoplasia, where it may have diagnostic utility. Initial studies in breast, lung and ovarian cancers indicated aberrant expression of ßV-tubulin, suggesting that this isoform may be associated with tumorigenesis. Thus, ßV-tubulin expression is a potentially promising prognostic marker of malignancy.


Subject(s)
Antibodies/immunology , Neoplasms/diagnosis , Neoplasms/metabolism , Tubulin/immunology , Tubulin/metabolism , Amino Acid Sequence , Animals , Antibody Specificity/immunology , Cell Line , Embryo, Mammalian/cytology , Fibroblasts/metabolism , Fluorescent Antibody Technique , Humans , Male , Mice , Molecular Sequence Data , Organ Specificity , Protein Isoforms/chemistry , Protein Isoforms/immunology , Protein Isoforms/metabolism , Rabbits , Tubulin/analysis , Tubulin/chemistry
2.
Oncotarget ; 2(1-2): 89-98, 2011.
Article in English | MEDLINE | ID: mdl-21399233

ABSTRACT

Senescence is a valid tumor suppressive mechanism in cancer. Accelerated cell senescence describes the growth arrested state of cells that have been treated with anti-tumor drugs, such as doxorubicin that induce a DNA damage response. Discodermolide, a microtubule-stabilizing agent, is a potent inducer of accelerated cell senescence. Resistance to discodermolide is mediated via resistance to accelerated cell senescence, and is associated with reduced expression of the mTORC1 substrate, 4E-BP1 and increased expression of p53 [1]. Although the association of p53 with senescence induction is well-characterized, senescence reversion in the presence of high expression of p53 has not been well-documented. Furthermore, studies addressing the role of mTOR signaling in regulating senescence have been limited and recent data implicate a novel, senescence-associated role for 4E-BP1 in crosstalk with the transcription factor p53. This research perspective will address these somewhat contradictory findings and summarize recent research regarding senescence and mTORC1 signaling.


Subject(s)
Adaptor Proteins, Signal Transducing/physiology , Cellular Senescence/drug effects , Cellular Senescence/physiology , Neoplasms/drug therapy , Neoplasms/pathology , Phosphoproteins/physiology , Tumor Suppressor Protein p53/physiology , Adaptor Proteins, Signal Transducing/genetics , Adaptor Proteins, Signal Transducing/metabolism , Cell Cycle Proteins , Cell Line, Tumor , Cellular Senescence/genetics , Genes, p53 , Humans , Molecular Targeted Therapy , Neoplasms/metabolism , Phosphoproteins/genetics , Phosphoproteins/metabolism , Tumor Suppressor Protein p53/genetics , Tumor Suppressor Protein p53/metabolism
3.
Proc Natl Acad Sci U S A ; 108(1): 391-6, 2011 Jan 04.
Article in English | MEDLINE | ID: mdl-21173253

ABSTRACT

Discodermolide is a microtubule-stabilizing agent that induces accelerated cell senescence. A discodermolide-resistant cell line, AD32, was generated from the human lung cancer cell line A549. We hypothesize that the major resistance mechanism in these cells is escape from accelerated senescence. AD32 cells have decreased levels of 4E-BP1 mRNA and protein, relative to the parental discodermolide-sensitive A549 cells. Lentiviral-mediated re-expression of wild-type 4E-BP1 in AD32 cells increased the proliferation rate and reverted resistance to discodermolide via restoration of discodermolide-induced accelerated senescence. Consistent with this, cell growth and response to discodermolide was confirmed in vivo using tumor xenograft models. Furthermore, reintroduction of a nonphosphorylatable mutant (Thr-37/46 Ala) of 4E-BP1 was able to partially restore sensitivity and enhance proliferation in AD32 cells, suggesting that these effects are independent of phosphorylation by mTORC1. Microarray profiling of AD32-resistant cells versus sensitive A549 cells, and subsequent unbiased gene ontology analysis, identified molecular pathways and functional groupings of differentially expressed mRNAs implicated in overcoming discodermolide-induced senescence. The most statistically significant classes of differentially expressed genes included p53 signaling, G2/M checkpoint regulation, and genes involved in the role of BRCA1 in the DNA damage response. Consistent with this, p53 protein expression was up-regulated and had increased nuclear localization in AD32 cells relative to parental A549 cells. Furthermore, the stability of p53 was enhanced in AD32 cells. Our studies propose a role for 4E-BP1 as a regulator of discodermolide-induced accelerated senescence.


Subject(s)
Adaptor Proteins, Signal Transducing/metabolism , Alkanes/pharmacology , Antineoplastic Agents/pharmacology , Carbamates/pharmacology , Cellular Senescence/drug effects , Drug Resistance, Neoplasm/physiology , Gene Expression Regulation/drug effects , Lactones/pharmacology , Phosphoproteins/metabolism , Pyrones/pharmacology , Tubulin Modulators/pharmacology , Adaptor Proteins, Signal Transducing/genetics , Animals , Cell Cycle Proteins , Cell Line, Tumor , Cell Proliferation/drug effects , Female , Fluorescent Antibody Technique , Genetic Vectors , Humans , Immunoblotting , Immunohistochemistry , Lentivirus , Mice , Microarray Analysis , Paclitaxel/pharmacology , Phosphoproteins/genetics , Transduction, Genetic , Tumor Suppressor Protein p53/metabolism , beta-Galactosidase/metabolism
SELECTION OF CITATIONS
SEARCH DETAIL
...